Introduction
============

Lung cancer is the most common cause of cancer-related death worldwide. Non-small-cell lung cancer (NSCLC) accounts for \>85% of primary lung cancers, and approximately two-thirds of NSCLC patients are diagnosed at an advanced stage.[@b1-ott-8-3361] Pathological features, such as pathological stage, histological type, and lymph node metastasis, have been independent prognostic markers predicting the development of metastasis.[@b2-ott-8-3361] However, they are imperfect, represent only crude measures of the biological behavior of a tumor, and cannot predict the optimal therapeutic course for the individual patient. Thus, it is important to identify biological markers which can predict survival.

The ability of cancer cells to avoid apoptosis and continue to proliferate is one of the fundamental hallmarks of cancer. B-cell-lymphoma-2 (Bcl-2) is a key regulator of the mitochondrial apoptotic pathway promoting survival by inhibition of adapters necessary for the activation and cleavage of caspases.[@b3-ott-8-3361] The *Bcl-2* gene was discovered in a follicular B-cell lymphoma, and its tumorigenic potential has been shown in animal models.[@b4-ott-8-3361] Bcl-2 is overexpressed in a variety of human tumors including lung cancer.[@b3-ott-8-3361],[@b5-ott-8-3361]

In lung cancer, the prognostic value of Bcl-2 expression has been analyzed by several groups, but results have been conflicting and controversial. One group investigated Bcl-2 expression in a meta-analysis of nine studies with a total of 673 small-cell lung cancer patients and concluded that Bcl-2 expression was associated with a better prognosis, but this did not reach significance.[@b6-ott-8-3361] Also, although there are a large number of studies investigating the prognostic value of Bcl-2 expression in NSCLC survival, no consensus has been reached. These conflicting results have been reported from different laboratories. We, therefore, carried out a meta-analysis of data from published studies to quantitatively review the effect of Bcl-2 overexpression in tumor tissue on overall survival (OS) in patients with NSCLC.

Materials and methods
=====================

Search strategy and study selection
-----------------------------------

The search was performed by consulting the electronic database PubMed, the Cochrane Library, and China National Knowledge Infrastructure. Searches included the terms "non-small cell lung cancer" and "Bcl-2". The keywords hit 553 citations. Manual selection of relevant studies was carried out based on the summary analysis. The citation lists of all retrieved articles were scanned to identify other potentially relevant reports.

The following criteria for eligibility among studies were set before collecting articles: 1) Bcl-2 expression was evaluated in primary NSCLC tissue. 2) Survival information at specific times was reported in the article. 3) Follow-up time exceeded 5 years. 4) Articles were published in English and in Chinese. 4) When several articles were published by the same authors or group, the newest or most informative single article was selected. Exclusion criteria were the following: 1) No information on survival was provided, or the hazard ratio (HR) of OS could not be calculated based on the given information. 2) Letters to editor, reviews, and articles published in a book or papers published in non-English. 3) Studies with radiotherapy or concurrent chemoradiotherapy treatment investigating response rates only.

Two authors (SW and JZ) did the search and identification independently, and selection of an article was reached by consensus. The following information was extracted from each report by the two authors independently: year of publication, patient size, time period of patient enrollment, patient source, histology, disease stage, test method, cutoff value, and survival data. If data from any of the above categories were not reported in the primary study, items were treated as "not applicable".

Quality assessment
------------------

Quality assessment of each study was performed using the Newcastle--Ottawa Quality Assessment Scale for cohort studies. This scale is an 8-item instrument that allows for assessment of patient population and selection, study comparability, follow-up, and outcome of interest. The scale was recommended by the Cochrane Non-Randomized Studies Methods Working Group. Two investigators (JZ and SW) performed quality assessment independently. Disagreement was resolved by consensus.

Statistical analysis
--------------------

Analysis of variance was used to compare the means of quality scores between different groups. For quantitative aggregation of survival results, HR and their 95% confidence intervals (CIs) were combined to give the effective value. The HR was calculated from the reported data directly by number of events. If data were presented in the form of Kaplan--Meier survival curve, we extracted them from the survival rates at specified times in order to reconstruct the HR estimate and its variance using methods reported by Parmar et al.[@b7-ott-8-3361] Data were entered into the Cochrane Collaboration software, RevMan Version 5.0 for Windows (the Cochrane Collaboration, Oxford, UK). The Cochran's test was used to assess the heterogeneity of included studies. For heterogeneity tests, *P*-value \<0.05 was considered to indicate significance. If the test of heterogeneity was significant (*P*\<0.05; *I*^2^\>50%), the random-effect model was used. Otherwise, the fixed-effect model was used. By convention, an observed HR of \<1 implied a better survival for the group with positive Bcl-2 expression. This impact of Bcl-2 on survival was considered as statistically significant if the 95% CI for the overall HR did not overlap.

Results
=======

Studies selection and characteristics
-------------------------------------

Five hundred and fifty-three potentially relevant citations were reviewed ([Figure 1](#f1-ott-8-3361){ref-type="fig"}). Among them, six studies were based on the same patient cohorts. Thus, the less informative ones were excluded (studies excluded were the following: Fontanini et al (1996), Laudanski et al (1995), and O'Byrne et al (2001); studies included were the following: Fontanini et al,[@b53-ott-8-3361] Laudanski et al,[@b35-ott-8-3361] and Cox et al[@b37-ott-8-3361]). Forty papers were review articles, 354 were not clinical studies including signal transduction, cell lines, animals, or pharmacogenomic studies, 13 were case reports, and the other 16 papers were designed without lung cancer. Ultimately, 50 studies[@b3-ott-8-3361],[@b8-ott-8-3361]--[@b56-ott-8-3361] that reported the prognostic value of Bcl-2 status for OS were analyzed. The total number of patients included was 6,863, ranging from 24 to 534 patients per study (median, 137). The major characteristics are shown in [Table 1](#t1-ott-8-3361){ref-type="table"}. These 50 studies included all lung cancer subtypes (n=46), adenocarcinomas only (n=2), or squamous cell carcinomas (SCCs) only (n=2). Twenty-nine studies had information for stages I--III, eight for advanced-stage (III--IV) disease, and 13 for all stages, I--IV. Forty-eight studies used immunohistochemistry to evaluate Bcl-2 expression, one used reverse transcription polymerase chain reaction, and one used Western blot.

In 50 studies evaluating Bcl-2 expression, the proportion of patients exhibiting Bcl-2 overexpression in individual studies ranged from 5% to 71%. Twenty-six out of the 50 studies identified Bcl-2 overexpression as an indicator of positive prognosis; Bcl-2 expression in six studies was significantly associated with poor prognosis. Eighteen studies showed no statistically significant impact of Bcl-2 overexpression on survival.

Quality assessment
------------------

We used the Newcastle--Ottawa Scale to perform quality assessment of all 50 studies. Studies that fulfill five or more of the eight criteria were higher quality studies. Overall, the total quality score of the included studies ranged from 5 to 8 ([Table 1](#t1-ott-8-3361){ref-type="table"}).

Impact of Bcl-2-positive expression on OS of NSCLC
--------------------------------------------------

The effect of Bcl-2 expression on OS was evaluated in 50 studies with a total of 6,863 patients. Overall, Bcl-2 was expressed in 33% of the NSCLCs studied. HRs were calculated from the reported data directly by number of events (25 out of 50), or data reading from Kaplan--Meier survival curve from the survival curves reading (25 out of 50). The combined HR was calculated using a random-effect model, and a value was obtained that was statistically significant (HR 0.79, 95% CI 0.72--0.87, *P*\<0.00001), indicating that Bcl-2-positive expression was an indicator of better prognosis.

The data extracted were adequate to aggregate the studies of stage I NSCLC. When we aggregated the eight studies which reported data from 1,432 patients, no heterogeneity was found. The combined HR was not statistically significant (HR 0.93, 95% CI 0.80--1.07, *P*=0.50). Thus, no relationship between Bcl-2 and survival was observed for stage I NSCLC ([Figure 2A](#f2-ott-8-3361){ref-type="fig"}).

When 29 studies containing 4,390 patients who had received radical surgery (I--III) were considered, highly significant heterogeneity was detected (*χ*^2^=92.48, *P*\<0.00001; *I*^2^=70%). The random-effect model was used to perform meta-analysis, and the result was significant in favor of patients with positive Bcl-2 expression (HR 0.77, 95% CI 0.69--0.89, *P*\<0.0001) ([Figure 2B](#f2-ott-8-3361){ref-type="fig"}).

The advanced-stage subgroup included eight studies comprising 425 patients. Because no heterogeneity was found in this subgroup (*χ*^2^=7.77, *P*=0.35; *I*^2^=10%), the fixed-effect model was used to perform meta-analysis. The aggregated survival data also showed a good survival prognosis where there was Bcl-2-positive expression (HR 0.74, 95% CI 0.59--0.94, *P*=0.01) ([Figure 2C](#f2-ott-8-3361){ref-type="fig"}).

Thirteen studies comprising 2,048 patients were included in the all-stage subgroup. The result of the test for heterogeneity was significant (*χ*^2^=52.56, *P*\<0.0001; *I*^2^=77%), and then, the combined HR was calculated using a random-effect model. Bcl-2 expression was not significantly associated with OS (HR 0.84, 95% CI 0.69--1.02, *P*=0.08) ([Figure 2D](#f2-ott-8-3361){ref-type="fig"}). There were not adequate data to aggregate studies of stage II or III disease.

The data extracted were also adequate to aggregate the studies of SCC and adenocarcinoma for subgroup analyses. When we aggregated seven studies that reported results for SCC, the combined HR was statistically significant (HR 0.54, 95% CI 0.32--0.90, *P*=0.02) ([Figure 2E](#f2-ott-8-3361){ref-type="fig"}). We observed no statistically significant effect of Bcl-2 expression on survival in patients with adenocarcinoma, however (HR 0.92, 95% CI 0.56--1.51, *P*=0.73) ([Figure 2F](#f2-ott-8-3361){ref-type="fig"}).

There were 32 studies from Europe and USA and 18 from East Asia. The combined HRs of East Asian studies and non-East Asian studies were 0.78 (95% CI 0.63--0.96, *P*\<0.0001) and 0.82 (95% CI 0.72--0.92, *P*\<0.0001), respectively. In both East Asian and European/USA populations, Bcl-2 expression was an indicator of better prognosis.

Discussion
==========

Identification of prognostic factors allows the definition of high-risk groups of patients for whom further specific therapy might be necessary and stratification should thus be performed in randomized trials.

A previous meta-analysis showed an association between Bcl-2 positivity and better survival of patients with lung cancer.[@b57-ott-8-3361] This analysis included 18 NSCLC, three neuroendocrine, and four small-cell lung cancer trials reported from 1993 to 1999. However, data were insufficient to evaluate the prognostic value of Bcl-2 in surgical cases. The effect of Bcl-2-positive expression on specific stage, such as stage I, advanced stages, and adenocarcinomas, was not assessed. We have improved upon that previous meta-analysis by including more recent studies and by generally using a more comprehensive search strategy.

In this meta-analysis, 50 published studies including 6,863 patients with lung cancer were included. Our analysis indicates that NSCLC patients with Bcl-2-positive expression have a better prognosis than those with Bcl-2-negative expression in both East Asian and non-East Asian study populations (HR 0.79, 95% CI 0.72--0.87, *P*\<0.00001). However, Bcl-2 expression seems to have no significant impact on survival of stage I NSCLC patients.

The mechanisms through which Bcl-2 might exert its protective effect in NSCLC are unclear. One group demonstrated that Bcl-2 expression showed an association with biologic features, such as the absence of c-erb-B2 and mutant p53 expression, which define a better prognosis.[@b58-ott-8-3361] Therefore, although *bcl-2* is a proto-oncogene involved in oncogenesis, because of its ability to prolong cell survival through the inhibition of apoptosis, its expression may be associated with other features that define a more favorable prognosis. Bcl-2 may also suppress the proliferative activity of tumor cells. It has been reported that the proliferative activity of Bcl-2-positive tumors tended to be lower than that in negative tumors.[@b51-ott-8-3361] Furthermore, the process of apoptosis involves many proteins such as antiapoptotic proteins (Bcl-2, Bcl-X) and proapoptotic proteins (Bax, Bak, Bad). Thus, it remains to be clarified if other proteins or bcl homologs potentiate the tumor suppressor role of Bcl-2 in NSCLC. Recently, Bcl-2 was found to inhibit DNA replication and DNA repair.[@b59-ott-8-3361],[@b60-ott-8-3361] Due to its dual function, NSCLC patients with Bcl-2-positive expression had a better prognosis than those with Bcl-2-negative expression in both Asian and non-Asian study populations in this analysis.

Some potentially important methodologic biases need to be discussed. When the analysis was limited to eight advanced-stage studies, or eight studies assessing Bcl-2 in stage I subgroup, heterogeneity was not detected. However, heterogeneity was detected when analyses were limited to the 18 East Asian studies or the seven studies including only SCC. Therefore, patient type and histologic type were not a major source of heterogeneity. The heterogeneity in this study could be explained by the stage or by differences in the method used to detect Bcl-2 status. Small sample size was also a source of bias. When the analysis was limited to \>100 patients in studies in surgical group, no significant heterogeneity was detected (*χ*^2^=35.29, *P*=0.01; *I*^2^=46%).

Additional biases could be introduced by the methodology used. We performed a methodological assessment of the studies to avoid selection biases where possible. The comparison of the scores of the three groups (positive, nonsignificant, negative studies) showed no statistically significant difference, allowing a meaningful data aggregation.

In conclusion, Bcl-2-positive expression was associated with a better prognosis in patients with NSCLC, so Bcl-2 might be a useful prognostic marker.[@b61-ott-8-3361] However, Bcl-2-positive expression seems to have no significant impact on survival of stage I patients as determined in our meta-analysis. These results should be confirmed by an adequately designed prospective study. Because there was only limited number of patients to test for Bcl-2 expression in platinum-based chemotherapy, these results need to be confirmed by well-designed prospective studies.
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###### 

Meta-analysis (Forest plot) of 50 studies assessing Bcl-2 in NSCLC.

**Notes:** (**A**) Forest plot of stage I group analysis; pooled data from eight studies did not show significant impact on survival with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.93, 95% CI 0.80--1.07, *P*=0.50). (**B**) Forest plot of stage I--III group analysis; pooled data from 29 studies showed that NSCLC patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.77, 95% CI 0.69--0.89, *P*\<0.0001). (**C**) Forest plot of stage III--IV group analysis; pooled data from eight studies showed that patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.74, 95% CI 0.59--0.94, *P*=0.01). (**D**) Forest plot of all stage group analysis; pooled data from 13 studies did not show significant impact on survival in patients with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.84, 95% CI 0.69--1.02, *P*=0.08). (**E**) Forest plot of SCC group analysis; pooled data from seven studies showed that patients with Bcl-2-positive expression have better prognosis than those with Bcl-2-negative expression (HR 0.54, 95% CI 0.32--0.90, *P*=0.02). (**F**) Forest plot of adenocarcinoma group analysis; pooled data from six studies did not show significant impact on survival in patients with Bcl-2-positive expression compared with those with Bcl-2-negative expression (HR 0.92, 95% CI 0.56--1.51, *P*=0.73).

**Abbreviations:** Bcl-2, B-cell-lymphoma-2; NSCLC, non-small-cell lung cancer; HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma.
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###### 

Baseline characteristics of the 50 trials used in the meta-analysis

  Studies                               Year   Patients source              Number of patients   Method   Stage        Study quality points
  ------------------------------------- ------ ---------------------------- -------------------- -------- ------------ ----------------------
  Cakir et al[@b8-ott-8-3361]           2011   Turkey                       166                  IHC      I--IV        6 out of 9
  Anagnostou et al[@b3-ott-8-3361]      2010   USA/Greece                   534                  IHC      I--IV        6 out of 9
  Grimminger et al[@b9-ott-8-3361]      2010   Germany                      91                   RT-PCR   I--IIIA      6 out of 9
  Jeong et al[@b10-ott-8-3361]          2010   Republic of Korea            39                   IHC      IIIA--IIIB   5 out of 9
  Porebska et al[@b11-ott-8-3361]       2009   Poland                       30                   IHC      I--IV        6 out of 9
  Lee et al[@b12-ott-8-3361]            2009   Republic of Korea            50                   IHC      IIIB--IV     7 out of 9
  Renouf et al[@b13-ott-8-3361]         2009   Canada                       451                  IHC      I--II        7 out of 9
  Zhao et al[@b14-ott-8-3361]           2008   People's Republic of China   62                   IHC      I--IIIA      6 out of 9
  Yoo et al[@b15-ott-8-3361]            2007   Republic of Korea            219                  IHC      I--III       6 out of 9
  Hu et al[@b16-ott-8-3361]             2006   People's Republic of China   88                   IHC      I--III       6 out of 9
  Wang et al[@b17-ott-8-3361]           2006   People's Republic of China   111                  IHC      I--III       6 out of 9
  Yaren et al[@b18-ott-8-3361]          2006   Turkey                       69                   IHC      I--IV        6 out of 9
  Yilmaz et al[@b19-ott-8-3361]         2005   Turkey                       46                   IHC      I--IV        6 out of 9
  Groeger et al[@b20-ott-8-3361]        2004   USA                          76                   IHC      I--IV        5 out of 9
  Shibata et al[@b21-ott-8-3361]        2004   Japan                        120                  IHC      I--III       7 out of 9
  Kren et al[@b22-ott-8-3361]           2004   USA                          102                  IHC      I--IIIA      6 out of 9
  Ludovini et al[@b23-ott-8-3361]       2004   Italy                        85                   IHC      IIIA--IV     7 out of 9
  Grossi et al[@b24-ott-8-3361]         2003   Italy                        213                  IHC      I--IIIA      5 out of 9
  Huang et al[@b25-ott-8-3361]          2003   USA                          91                   WB       I--IV        6 out of 9
  Gregorc et al[@b26-ott-8-3361]        2003   Italy                        102                  IHC      IIIA--IV     7 out of 9
  Han et al[@b27-ott-8-3361]            2003   Republic of Korea            34                   IHC      IIIB--IV     6 out of 9
  Krug et al[@b28-ott-8-3361]           2003   USA                          31                   IHC      IIIB--IV     8 out of 9
  Poleri et al[@b29-ott-8-3361]         2003   Argentina                    53                   IHC      I            8 out of 9
  Tomita et al[@b30-ott-8-3361]         2003   Japan                        60                   IHC      IIIA--IV     7 out of 9
  Lai et al[@b31-ott-8-3361]            2002   Taiwan                       114                  IHC      I--IIIA      6 out of 9
  Hanaoka et al[@b32-ott-8-3361]        2002   Japan                        70                   IHC      I--III       6 out of 9
  Han et al[@b33-ott-8-3361]            2002   USA                          85                   IHC      I            7 out of 9
  Hwang et al[@b34-ott-8-3361]          2001   Republic of Korea            53                   IHC      I--IIIB      6 out of 9
  Laudanski et al[@b35-ott-8-3361]      2001   Poland                       102                  IHC      I--IIIA      6 out of 9
  Tanaka et al[@b36-ott-8-3361]         2001   Japan                        162                  IHC      I            8 out of 9
  Cox et al[@b37-ott-8-3361]            2000   USA                          178                  IHC      I--IIIA      6 out of 9
  Moldvay et al[@b38-ott-8-3361]        2000   France                       226                  IHC      I--IV        7 out of 9
  van de Vaart et al[@b39-ott-8-3361]   2000   the Netherlands              24                   IHC      IIIA--IIIB   6 out of 9
  Chen et al[@b40-ott-8-3361]           1999   Japan                        40                   IHC      I            7 out of 9
  D'Amico et al[@b41-ott-8-3361]        1999   USA                          408                  IHC      I            8 out of 9
  Huang et al[@b42-ott-8-3361]          1999   Japan                        203                  IHC      I--IIIB      8 out of 9
  Mehdi et al[@b43-ott-8-3361]          1999   USA                          241                  IHC      I--II        6 out of 9
  Silvestrini et al[@b44-ott-8-3361]    1998   Italy                        101                  IHC      I--III       7 out of 9
  Anton et al[@b45-ott-8-3361]          1997   USA                          427                  IHC      I--IV        8 out of 9
  Apolinario et al[@b46-ott-8-3361]     1997   the Netherlands              116                  IHC      I--IIIA      6 out of 9
  Higashiyama et al[@b47-ott-8-3361]    1997   Japan                        174                  IHC      I--IIIB      6 out of 9
  Ishida et al[@b48-ott-8-3361]         1997   Japan                        114                  IHC      I--IIIA      6 out of 9
  Koukourakis et al[@b49-ott-8-3361]    1997   USA                          107                  IHC      I--IIIA      6 out of 9
  Pastorino et al[@b50-ott-8-3361]      1997   UK                           485                  IHC      I            7 out of 9
  O'Neill et al[@b51-ott-8-3361]        1996   Ireland                      54                   IHC      I--IV        5 out of 9
  Ohsaki et al[@b52-ott-8-3361]         1996   Japan                        99                   IHC      I--IV        6 out of 9
  Fontanini et al[@b53-ott-8-3361]      1995   Italy                        89                   IHC      I--IIIA      5 out of 9
  Ritter et al[@b54-ott-8-3361]         1995   USA                          126                  IHC      I            7 out of 9
  Walker et al[@b55-ott-8-3361]         1995   UK                           27                   IHC      I--IV        6 out of 9
  Pezzella et al[@b56-ott-8-3361]       1993   UK                           115                  IHC      I--III       7 out of 9

**Abbreviations:** IHC, immunohistochemistry; RT-PCR, reverse transcription polymerase chain reaction; WB, Western blot.
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